Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBITDA: 2010-2024

Historic EBITDA for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$83.7 million.

  • Northwest Biotherapeutics' EBITDA fell 22.02% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.4 million, marking a year-over-year decrease of 25.90%. This contributed to the annual value of -$83.7 million for FY2024, which is 26.83% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its EBITDA stood at -$83.7 million for FY2024, which was down 26.83% from -$66.0 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' EBITDA ranged from a high of -$52.7 million in FY2021 and a low of -$86.6 million during FY2020.
  • Moreover, its 3-year median value for EBITDA was -$67.2 million (2022), whereas its average is -$72.3 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' EBITDA crashed by 209.54% in 2020 and then soared by 39.15% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' EBITDA (Yearly) stood at -$86.6 million in 2020, then surged by 39.15% to -$52.7 million in 2021, then declined by 27.47% to -$67.2 million in 2022, then climbed by 1.78% to -$66.0 million in 2023, then dropped by 26.83% to -$83.7 million in 2024.